Al's Comment:

Exciting report.  This combination of the drugs drugs atezolizumab and ipatasertib were tried on 10 glioblastoma patients. They report two patients did very well, and these patients had a PTEN mutation. Atezolizumab is a PDL1 inhibitor, and is easily available.  Ipatasertib is an experimental  small molecule inhibitor of AKT and hard to get.  I would like to see this tried in a larger trial.


Posted on: 04/10/2021

Immunotherapy combination shows early promise in aggressive brain cancers


Click HERE to return to brain tumor news headlines.